Post-earnings recap
Reported
Wed, Apr 27, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Viking Therapeutics reported a loss that was slightly worse than expected, which contributed to a decline in stock price by nearly 4%. The lack of revenue information and forward guidance may leave investors uncertain about the company's near-term prospects. The stock reaction reflects a cautious sentiment among investors as they await further developments in Viking's clinical programs.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | -7.14% |
| Revenue | N/A | N/A | N/A |
Management expressed a commitment to their ongoing clinical trials but did not offer specific insights into future performance. The tone was cautious regarding market conditions.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its clinical programs.